


## Supplemental Data

# Reduction of Cardiac Cell Death after Helium Postconditioning in Rats: Transcriptional Analysis of Cell Death and Survival Pathways


Gezina TML Oei,<sup>1</sup> Michal Heger,<sup>2</sup> Rowan F van Golen,<sup>2</sup> Lindy K Alles,<sup>2</sup> Moritz Flick,<sup>1</sup> Allard C van der Wal,<sup>3</sup> Thomas M van Gulik,<sup>2</sup> Markus W Hollmann,<sup>1</sup> Benedikt Preckel,<sup>1</sup> and Nina C Weber<sup>1</sup>

Online address: <http://www.molmed.org>

The Feinstein Institute  
for Medical Research    North Shore LIJ  
Empowering Imagination. Pioneering Discovery.<sup>®</sup>



**Supplementary Figure S1.** Literature overview of infarct size reduction after helium preconditioning. Summary of literature in which infarct sizes are plotted as a percentage of area at risk after helium preconditioning. Data are plotted as means. At the bottom of the figure an overview of the absolute infarct size reduction is given. Infarct size reduction by early preconditioning (EPC) entails application of 5-min cycles of helium inhalation before the ischemic episode. EPC1, EPC3 and EPC5 consist of 1, 3 or 5 5-min cycles of helium before ischemia, respectively. Late preconditioning (LPC) is based on 15 min of helium administration 24 h before the ischemic episode and also results in infarct size reduction. Rat experiments: 25 min of ischemia and 2 h of reperfusion, rabbit experiments 30 min of ischemia and 3 h of reperfusion. A (1): n=8 per group, EPC3; B (2): n=8 per group, EPC3; C (3): n=10 per group, EPC3; D (4): n=8-12 per group, LPC; E (5): n=6 per group, EPC3; F (6): n=6/7 per group, EPC3, EPC1; D (7): n=7/8 per group, EPC3; G (8): n=6/7 per group, EPC5, EPC3, EPC1; H (9): n=8 per group, EPC3; I (10): n=8 per group, EPC3.



**Supplementary Figure S2.** Preparation of histological slices. Hearts were cut in two parts, crossing the previous ligation of the LAD.

**Supplementary Table S1.** RNA extraction, cDNA synthesis and run parameters.

Program name	Target (°C)	Acquisition Mode	Hold (hh:mm:ss)	Ramp Rate (°C/s)	Acquisition (per °C)	Sec Target (°C)	Step Size (°C)	Step Delay (cycles)	Cycles	Analysis mode
Heat activation	95	none	00:10:00	4.4		0	0	0		
PCR cycle	95	none	00:00:15	1.0		0	0	0	50	quantification
	60	single	00:01:00	1.0		0	0	0		
Melting curves	60	none	00:00:15	4.4						
	95	continuous		0.03	20					

RNA was extracted from heart tissue using the RNeasy Fibrous Tissue Mini Kit (Qiagen, Venlo, The Netherlands) according to manufacturer's instructions. All materials and reagents used in the procedure were from Qiagen, unless stated otherwise. In brief, ±30 mg of heart tissue was added to 300 µL of RLT lysis buffer containing 1% (v/v) β-mercaptoethanol and homogenized with a MagNA Lyser using MagNA Lyser Green Beads (both from Roche Applied Sciences, Penzberg, Germany). The lysate was collected and 600 µL of nuclease-free water containing 1.67% (v/v) proteinase K was added to digest residual fibrous tissue (6 min at 55°C). Total RNA was extracted using spin columns, including on-column DNase I treatment, and eluted in 30 µL of nuclease-free water. Next, eluate RNA concentrations were determined by UV-vis absorbance spectroscopy (NanoDrop, Thermo Scientific, Rockford IL). RNA yields typically ranged from 0.3 to 3 µg/µL (data not shown). To ensure RNA purity, samples with an A260/A280 ratio of ≤1.99 were excluded from further analysis.

Next, 1 µg of RNA was reverse transcribed to cDNA, using the RT<sup>2</sup> First Strand Kit according to manufacturer's instructions. RNA was reverse transcribed to cDNA using the RT<sup>2</sup> First Strand Kit (Qiagen, catalogue number #330401) according to manufacturer's instructions. Before starting the procedure, the RNA concentration of all samples was diluted to 250 ng/µL with nuclease-free water. Next, 1 µg (4 µL) of RNA was mixed with 2 µL of GE-buffer and 2 µL of nuclease-free water and incubated at 42°C for 5 min to eliminate any residual DNA.

Following incubation at 4°C (1 min), 10 µL of reverse transcriptase mix was added to each 10 µL sample and reverse transcription was started by incubating the samples at 42°C for 15 min and subsequently terminated by raising the temperature to 92°C for 5 min. Last, 91 µL of nuclease-free water was added to each sample.

For optimal temperature control, cDNA synthesis was performed on a PTC-200 thermal cycler (MJ Research, Waltham, MA). cDNA was subsequently mixed with RT<sup>2</sup> SYBR Green qPCR Mastermix and nuclease-free water according to the manufacturer's instructions, loaded (25 µL/well) onto the Rat Cell Death PathwayFinder PCR Array (SABiosciences catalogue number #PARN-212A), and run on a LightCycler 480 (Roche Applied Sciences).

**Supplementary Table S2.** Gene descriptions.

Gene abbreviation	Category	Gene Description	Gene name
<i>Abl1</i>	pro-apoptosis	C-abl oncogene 1, <b>non-</b> receptor tyrosine kinase	<i>Abl</i>
<i>Akt1</i>	anti-apoptosis, autophagy	V-akt murine thymoma viral oncogene homolog 1	<i>Akt</i>
<i>Apaf1</i>	pro-apoptosis	Apoptotic peptidase activating factor 1	-
<i>App</i>	autophagy	Amyloid beta (A4) precursor protein	-
<i>Atg12</i>	autophagy	ATG12 autophagy related 12 homolog (S. cerevisiae)	<i>Apg12l</i> , MGC125080
<i>Atg16l1</i>	autophagy	ATG16 autophagy related 16-like 1 (S. cerevisiae)	<i>Apg16l</i> , <i>Wdr30</i>
<i>Atg3</i>	autophagy	ATG3 autophagy related 3 homolog (S. cerevisiae)	<i>Apg3l</i> , <i>PIG-1</i> , <i>Pig1</i>
<i>Atg5</i>	autophagy	ATG5 autophagy related 5 homolog (S. cerevisiae)	-
<i>Atg7</i>	autophagy	ATG7 autophagy related 7 homolog (S. cerevisiae)	<i>Apg7l</i>
<i>Atp6v1g2</i>	necrosis, pro-apoptosis	ATPase, H <sub>+</sub> transporting, lysosomal V1 subunit G2	<i>ATP6G</i> , <i>Atp6g2</i> , <i>NG38</i>
<i>Bax</i>	pro-apoptosis, autophagy	Bcl2-associated X protein	-
<i>Bcl2</i>	anti-apoptosis, autophagy	B-cell CLL/lymphoma 2	<i>Bcl-2</i>
<i>Bcl2a1d</i>	anti-apoptosis	B-cell leukemia/lymphoma 2 related protein A1d	<i>Bcl2a1</i>
<i>Bcl2l1</i>	anti-apoptosis, autophagy	Bcl2-like 1	<i>Bcl-xl</i> , <i>Bcl2l</i> , <i>Bclx</i> , <i>bcl-X</i>
<i>Bcl2l11</i>	pro-apoptosis	BCL2-like 11 (apoptosis facilitator)	<i>Bim</i> , <i>BimL</i>
<i>Beclin1</i>	autophagy	Beclin 1, autophagy related	-
<i>Birc2</i>	anti-apoptosis (11)	Baculoviral IAP repeat-containing 2	<i>Api2</i> , <i>rIAP1</i>
<i>Birc3</i>	anti-apoptosis	Baculoviral IAP repeat-containing 3	<i>Birc2</i> , <i>IAP1</i> , MGC93416
<i>Bmf</i>	necrosis	Bcl2 modifying factor	-
<i>Casp1</i>	pro-apoptosis	Caspase 1	<i>Ice</i> , <i>II1bc</i>
<i>Casp2</i>	anti-apoptosis/proapoptosis	Caspase 2	-
<i>Casp3</i>	pro-apoptosis, autophagy	Caspase 3	<i>Lice</i> , MGC93645

Continued on next page

Supplementary Table S2. Continued.

<i>Casp6</i>	pro-apoptosis	Caspase 6	MGC93335, Mch2
<i>Casp7</i>	pro-apoptosis	Caspase 7	-
<i>Casp9</i>	pro-apoptosis	Caspase 9, apoptosis-related cysteine peptidase	Apaf3, Casp-9-CTD, Casp9_v1, Ice-Lap6, Mch6
<i>Cd40</i>	pro-apoptosis	CD40 molecule, TNF receptor superfamily member 5	Tnfrsf5
<i>Cd40lg</i>	pro-apoptosis	CD40 ligand	Tnfsf5
<i>Cflar</i>	pro-apoptosis?	CASP8 and FADD-like apoptosis regulator	Flip, MGC108616
<i>Comm4d</i>	necrosis	COMM domain containing 4	-
<i>Ctsb</i>	autophagy	Cathepsin B	-
<i>Ctss</i>	autophagy	Cathepsin S	-
<i>Cybb</i>	necrosis	Cytochrome b-245, beta polypeptide	Gp91-phox, Nox2
<i>Cyld</i>	necrosis, pro-apoptosis	Cylindromatosis (turban tumor syndrome)	LRRGT00003, Rp1, Rp1h
<i>Defb1</i>	necrosis	Defensin beta 1	-
<i>Dffa</i>	Anti-apoptosis (12)	DNA fragmentation factor, alpha subunit	ICAD-S
<i>Dpysl4</i>	necrosis	Dihydropyrimidinase-like 4	Crmp3, Dpys4
<i>Esr1</i>	autophagy	Estrogen receptor 1	ER-alpha, Esr, RNESTROR
<i>Fas</i>	pro-apoptosis, autophagy	Fas (TNF receptor superfamily, member 6)	Tnfrsf6
<i>Faslg</i>	pro-apoptosis	Fas ligand (TNF superfamily, member 6)	Apt1Lg1, CD95-L, Fast, Tnfsf6
<i>Foxi1</i>	necrosis	Forkhead box I1	-
<i>Gaa</i>	autophagy	Glucosidase, alpha, acid	MGC72625
<i>Gadd45a</i>	pro-apoptosis	Growth arrest and DNA-damage-inducible, alpha	Ddit1, Gadd45
<i>Galnt5</i>	necrosis	UDP-N-acetyl-alpha-D-galactosamine:polypeptide N-acetylgalactosaminyltransferase 5 (GalNAc-T5)	-
<i>Grb2</i>	necrosis	Growth factor receptor bound protein 2	MGC108668
<i>Hspbap1</i>	necrosis	Hspb associated protein 1	Pass1
<i>Htt</i>	autophagy	Huntingtin	Hd, Hdh
<i>Ifng</i>	autophagy	Interferon gamma	IFNG2
<i>Igf1</i>	autophagy	Insulin-like growth factor 1	-
<i>Igf1r</i>	anti-apoptosis	Insulin-like growth factor 1 receptor	IGFIRC, JTK13
<i>Ins2</i>	autophagy	Insulin 2	-
<i>Irgm</i>	autophagy	Immunity-related GTPase family, M	If1
<i>Kcnip1</i>	necrosis	Kv channel-interacting protein 1	Kchip1
<i>Map1lc3a</i>	autophagy	Microtubule-associated protein 1 light chain 3 alpha	MGC105263
<i>Mapk8</i>	autophagy	Mitogen-activated protein kinase 8	JNK
<i>Mcl1</i>	anti-apoptosis/proapoptose	Myeloid cell leukemia sequence 1	-
<i>Nfkb1</i>	autophagy	Nuclear factor of kappa light polypeptide gene enhancer in B-cells 1	NF-kB
<i>Nol3</i>	anti-apoptosis (13)	Nucleolar protein 3 (apoptosis repressor with CARD domain)	Arc
<i>Olr1583</i>	necrosis	Olfactory receptor 1583	-
<i>Parp2</i>	necrosis	Poly (ADP-ribose) polymerase 2	Adprt2
<i>Pik3c3</i>	autophagy	Phosphoinositide-3-kinase, class 3	-
<i>Pten</i>	autophagy	Phosphatase and tensin homolog	MMAC1, Mmac, TEP1
<i>Pvr</i>	necrosis	Poliovirus receptor	Taa1, Tage4
<i>Rab25</i>	necrosis	RAB25, member RAS oncogene family	-
<i>RGD1311517</i>	necrosis	Similar to RIKEN cDNA 9430015G10	-
<i>RGD1562639</i>	necrosis	Similar to c-myc promoter binding protein	-
<i>Rps6kb1</i>	autophagy	Ribosomal protein S6 kinase, polypeptide 1	-
<i>Snc1</i>	autophagy	Synuclein, alpha (non A4 component of amyloid precursor)	MGC105443
<i>Spata2</i>	necrosis, pro-apoptosis?	Spermatogenesis associated 2	MGC93291
<i>Sqstm1</i>	autophagy	Sequestosome 1	Osi, ZIP, ZIP3
<i>Sycp2</i>	necrosis, pro-apoptosis?	Synaptonemal complex protein 2	-
<i>Tmem57</i>	necrosis	Transmembrane protein 57	MGC116145
<i>Tnf</i>	pro-apoptosis, autophagy	Tumor necrosis factor (TNF superfamily, member 2)	MGC124630, RATTNF, TNF-alpha, Tnfa
<i>Tnfrsf10b</i>	pro-apoptosis	Tumor necrosis factor receptor superfamily, member 10b	-
<i>Tnfrsf11b</i>	anti-apoptosis	Tumor necrosis factor receptor superfamily, member 11b	MGC93568, Opg
<i>Tnfrsf4</i>	necrosis	Tumor necrosis factor receptor superfamily, member 4	Ox40, Txgp1
<i>Tnfrsf8</i>	necrosis	Tumor necrosis factor receptor superfamily, member 8	Cd30
<i>Tp53</i>	pro-apoptosis, autophagy	Tumor protein p53	MGC112612, Trp53, p53
<i>Traf2</i>	anti-apoptosis	Tnf receptor-associated factor 2	-
<i>Txnl4b</i>	necrosis	Thioredoxin-like 4B	MGC109322, RGD1305127
<i>Ulk1</i>	autophagy	Unc-51 like kinase 1 (C. elegans)	-
<i>Xiap</i>	anti-apoptosis	X-linked inhibitor of apoptosis	Api3, Birc4, riap3

## METHODS: WESTERN BLOTT ANALYSIS

### Preparation of Cytosol, Membrane and Mitochondrial fractions


Excised hearts were shock-frozen in liquid nitrogen and pulverized in a pre-cooled mortar. Samples were dissolved in lysis buffer containing Tris base, EGTA, NaF and  $\text{Na}_3\text{VO}_4$  (as phosphatase inhibitors), an inase-inhibitor mix (aprotinin, leupetin and Pepsatin), DTT and okadaic acid. The solution was homogenized on ice (Homogenisator, Ultra-Turrax T8) and centrifuged slowly at 1000 g, 4°C for 10 min. The remaining supernatant was pipetted in new vials and centrifuged at 10000 g, from which a pellet remained containing the mitochondria. The supernatant was re-centrifuged at 12000 g to obtain a cytosolic fraction. The remaining pellet was sus-

pended in lysis buffer (containing 1% Triton X-100), incubated for 60 min on ice and vortexed. The solution was centrifuged at 16000 g for 15 min, resulting in a supernatant containing the membrane fraction. All fractions were stored at -80°C.


### Western Blot Analysis

After protein determination by the Bradford method (14), equal amounts of protein were mixed with sample buffer (containing SDS, Bromophenol Blue, Tris Base, Glycerol and Mercaptoethanol). Samples were vortexed, boiled at 95°C for 5 min, and loaded on a Criterion Gel. Proteins were separated by electrophoresis and transferred onto Immobilin-FL Membrane. Unspecific binding of the antibody was blocked by incubation with Odyssey® Blocking Buffer for 60 min.


Subsequently, the membrane was incubated over night at 4°C with Beclin1 (Cell Signaling Technology, 1:1000) or Sequestosome1 (Abcam, 1:2000) antibody. After washing in fresh, cold TBS-T, the blot was subjected to the appropriate horseradish peroxidase conjugated secondary antibody for 1 h at room temperature, subsequently, immunoreactive bands were visualized by the Odyssey® Infrared Imaging System. The Odyssey® Infrared Scanning Software was used for quantification of the blots. Results are presented as the ratio of the target protein over the fraction-specific control protein: for the cytosol fraction this was actin (1:5000), for the membrane fraction NaKATPase (Cell Signaling Technology, 1:5000) and for the mitochondrial fraction AntiPHB1 (Cell Signaling Technology, 1:10000).




**Supplementary Figure S3.** Histology – Sham. Representative slices of three sham animals, 200 times enlarged. The pictures clearly show normally structured cardiomyocytes without edema or signs of cell damage.




**Supplementary Figure S4.** Histology – Ischemia. Representative slices of three animals that underwent 25 min of ischemia, 200 times enlarged. Arrows indicate ischemic hypercontraction, E indicates edema.




**Supplementary Figure S5.** Histology – I/R5. Representative slices of three animals that were exposed to 25 min of ischemia and 5 min of reperfusion, 200 times enlarged. E indicates edema, RBC indicates extravasation of red blood cells and asterisk indicates contraction band necrosis.




**Supplementary Figure S6.** Histology – I/R15. Representative slices of three animals that were exposed to 25 min of ischemia and 15 min of reperfusion, 200 times enlarged. E indicates edema, RBC indicates extravasation of red blood cells, GRA indicates extravasation of granulocytes and asterisk indicates contraction band necrosis.




**Supplementary Figure S7.** Histology – I/R30. Representative slices of three animals that were exposed to 25 min of ischemia and 30 min of reperfusion, 200 times enlarged. E indicates edema, RBC indicates extravasation of red blood cells, GRA indicates extravasation of granulocytes and stars indicate contraction band necrosis.




**Supplementary Figure S8.** Histology – He5. Representative slices of three animals that were exposed to 25 min of ischemia and 5 min of reperfusion with helium postconditioning for 5 min, 200 times enlarged. Arrows indicate hypercontracture, E indicates edema, RBC indicates extravasation of red blood cells, GRA indicates extravasation of granulocytes, P indicates presence of platelets and thrombi and asterisk indicates contraction band necrosis.




**Supplementary Figure S9.** Histology – He15. Representative slices of three animals that were exposed to 25 min of ischemia and 15 min of reperfusion with helium postconditioning for 15 min, 200 times enlarged. GRA indicates extravasation of granulocytes, P indicates presence of platelets and thrombi, and asterisk indicates contraction band necrosis.



**Supplementary Figure S10.** Histology – He30. Representative slices of three animals that were exposed to 25 min of ischemia and 30 min of reperfusion with helium postconditioning for 30 min, 200 times enlarged. E indicates edema, RBC indicates extravasation of red blood cells, GRA indicates extravasation of granulocytes, P indicates presence of platelets and thrombi and asterisk indicates contraction band necrosis.



**Supplementary Figure S12.** Infarct sizes. Infarct sizes as percentage of area at risk. Data are plotted as mean  $\pm$  S.E.M. \* refers to statistical significance of HePOC vs CON. Below the graph, representative TTC-stained cross-sections of myocardium are shown for the control (CON) and 15-min HePOC group. Infarct sizes from 3 earlier studies (2,15,16) were compiled and analyzed using an unpaired Student *t* test.



**Supplementary Figure S11.** Protein levels Sequestosome. Data are shown as mean  $\pm$  S.E.M. On the y-axis integrated intensity as (A) ratio of SQSTM/actin (cytosol fraction), (B) ratio of SQSTM/NaKATPase, (C) ratio of SQSTM/PHB1. AAR = area at risk, NAAR = rest of the myocardium, area not at risk.

## REFERENCES

- 1 . Huhn R, Weber NC, Preckel B, Schlack W, Bauer I, et al. (2012) Age-related loss of cardiac preconditioning: impact of protein kinase A. *Exp Gerontol.* 47: 116-21.
- 2 . Huhn R, Heinen A, Weber NC, Kerindongo RP, Oei GT, et al. (2009) Helium-induced early preconditioning and postconditioning are abolished in obese Zucker rats in vivo. *J Pharmacol Exp Ther.* 329: 600-7.
- 3 . Heinen A, Huhn R, Smeele KM, Zuurbier CJ, Schlack W, et al. (2008) Helium-induced preconditioning in young and old rat heart: impact of mitochondrial Ca(2+)-sensitive potassium channel activation. *Anesthesiology.* 109: 830-6.
- 4 . Huhn R, Heinen A, Weber NC, Hieber S, Hollmann MW, et al. (2009) Helium-induced late preconditioning in the rat heart in vivo. *Br J Anaesth.* 102: 614-9.
- 5 . Pagel PS, Krolikowski JG. (2009) Transient metabolic alkalosis during early reperfusion abolishes helium preconditioning against myocardial infarction: restoration of cardioprotection by cyclosporin A in rabbits. *Anesth Analg.* 108: 1076-82.
- 6 . Pagel PS, Krolikowski JG, Amour J, Warltier DC, Weirrauch D. (2009) Morphine reduces the threshold of helium preconditioning against myocardial infarction: the role of opioid receptors in rabbits. *J Cardiothorac Vasc Anesth.* 23: 619-24.
- 7 . Pagel PS, Krolikowski JG, Shim YH, Venkatapuram S, Kersten JR, et al. (2007) Noble gases without anesthetic properties protect myocardium against infarction by activating prosurvival signaling kinases and inhibiting mitochondrial permeability transition in vivo. *Anesth Analg.* 105: 562-9.
- 8 . Pagel PS, Krolikowski JG, Pratt PF, Shim YH, Amour J, et al. (2008) Inhibition of glycogen synthase kinase or the apoptotic protein p53 lowers the threshold of helium cardioprotection in vivo: the role of mitochondrial permeability transition. *Anesth Analg.* 107: 769-75.
- 9 . Pagel PS, Krolikowski JG, Pratt PF, Shim YH, Amour J, et al. (2008) The mechanism of helium-induced preconditioning: a direct role for nitric oxide in rabbits. *Anesth Analg.* 107: 762-8.
- 10 . Pagel PS, Krolikowski JG, Pratt PF, Shim YH, Amour J, et al. (2008) Reactive oxygen species and mitochondrial adenosine triphosphate-regulated potassium channels mediate helium-induced preconditioning against myocardial infarction in vivo. *J Cardiothorac Vasc Anesth.* 22: 554-9.
- 11 . Saleem M, Qadir MI, Perveen N, Ahmad B, Saleem U, et al. (2013) Inhibitors Of Apoptotic Proteins: New Targets For Anti-Cancer Therapy. *Chem Biol Drug Des.* .
- 12 . Enari M, Sakahira H, Yokoyama H, Okawa K, Iwamatsu A, Nagata S. (1998) A caspase-activated DNase that degrades DNA during apoptosis, and its inhibitor ICAD. *Nature.* 391: 43-50.
- 13 . Lu X, Moore PG, Liu H, Schaefer S. (2011) Phosphorylation of ARC is a critical element in the antiapoptotic effect of anesthetic preconditioning. *Anesth Analg.* 112: 525-31.
- 14 . Bradford MM. (1976) A rapid and sensitive method for the quantitation of microgram quantities of protein utilizing the principle of protein-dye binding. *Anal Biochem.* 72: 248-54.
- 15 . Oei GT, Hollmann MW, Preckel B, Weber NC. (2012) Cardioprotection after a short episode of 70% helium inhalation at early reperfusion is abrogated by prolonged inhalation during reperfusion. *American Society of Anesthesiologists.* Abstract A151.
- 16 . Oei GT, Huhn R, Heinen A, Hollmann MW, Schlack WS, et al. (2012) Helium-induced cardioprotection of healthy and hypertensive rat myocardium in vivo. *Eur J Pharmacol.* 684: 125-31.